Fleming JR, Rani A, Kraft J, Zenker S, *Börgeson E, Lange S. Exploring Obscurin and SPEG Kinase Biology. J. Clin. Med. 2021 doi: 10.3390/jcm10050984.
Stronczek C, Lange S, Bullard B, Wolniak S, Börgeson E, Mayans O, and Fleming JR. Unique structural configuration of the titin N2A region Journal of General Physiology. (Accepted for publication)
Zhou T, Fleming JR, Lange S, Hessel A, Bogomolovas J, Stronczek C, Grundei D, Ghassemian M, Biju A, Börgeson E, Bullard B, Linke W, Chen J, Kovermann M, Mayans O. Molecular characterization of titin N2A and its complexation of CARP suggests a titin/actin cross-linking mechanism. Journal of Molecular Biology. PMID: 33647290DOI: 10.1016/j.jmb.2021.166901
Soták M, Casselbrant A, Rath E, Zietek T, Strömstedt M, Adingupu DD, Karlsson D, Fredin MF, Ergang P, Pácha J, Batorsky A, Alpers CE, Börgeson E, Hansen PBL, Ericsson A, Granqvist AB, Wallenius V, Fändriks L, Unwin RJ. Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity. Life Sci. 2020 Dec 29:118974. PMID: 33385407. doi: 10.1016/j.lfs.2020.118974.
Rajan MR, Sotak M, Barrenäs F, Shen T, Borkowski K, Ashton NJ, Biörserud C, Lindahl TL, Ramström S, Schöll M, Lindahl P, Fiehn O, Newman JW, Perkins R, Wallenius V, Lange S, Börgeson E*. Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Sci Rep. 2019 Oct 28;9(1):15385. doi: 10.1038/s41598-019-51673-0. PMID: 31659186. *Corresponding author.Weblink.
Lange S, Banerjee I, Carrion K, Serrano R, Habich L, Kameny R, Lengenfelder L, Dalton N, Meili R, Börgeson E, Peterson K, Ricci M, Lincoln J, Ghassemian M, Fineman J, Del Álamo JC, Nigam V. miR-486 is modulated by stretch and increases ventricular growth. JCI Insight. 2019 Sep 12;4(19). doi: 10.1172/jci.insight.125507. PubMed PMID: 31513548; PubMed Central PMCID: PMC6795397. Weblink.
Hernandez-Carretero A, Weber N, La Frano MR, Ying W, Lantero Rodriguez J, Sears DD, Wallenius V, Börgeson E, Newman JW, Osborn O. Obesity-induced changes in lipid mediators persist after weight loss. Int J Obes (Lond). 2018 Apr;42(4):728-736. doi: 10.1038/ijo.2017.266. Epub 2017 Nov 1. PubMed PMID: 29089614; PubMed Central PMCID: PMC6055936. Weblink.
Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K. AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia. 2017; 60(4):729-739. PMID: 28188334 Weblink.
Zhong L, Ding Y, Bandyopadhyay G, Waaler J, Börgeson E, Smith S, Phillips S, Mahooti S, Mahata S, Shao J, Krauss S, Chi N-W. The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose homeostasis in mice, Diabetologia, 2016 Mar;59(3):582-91, PMID: 26631215. Weblink.
Börgeson E*, Johnsson A, Lee Y.S., Till A, Syed H, Ali-Shah, Guiry P, Dalli D, Colas R, Serhan CN, Godson C, Sharma K. Lipoxin A4 attenuates obesity-induced adipose inflammation, liver and kidney disease. Cell Metabolism 2015 Jul 7;22(1):125-37, PMID:26052006. *Corresponding author.Weblink.
Corcoran JB, McCarthy, Griffin B, Gaffney A, Bhreathnach U, Börgeson E, Hickey FB, Docherty NG, Higgins DF, Furlong F, Martin F, Godson C, Murphy M. IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-β1-induced fibrotic responses. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013 Aug;1833(8):1969-78, PMID: 23567938. Weblink.
Brennan EP, Nolan KA, Börgeson E, Gough OS, McEvoy CM, Docherty NG, Higgins DF, Murphy M, Sadlier DM, Ali-Shah ST, Guiry PJ, Savage DA, Maxwell AP, Martin F, Godson C. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. Journal of the American Society of Nephrology, 2013 Mar;24(4):627-37, PMID: 23520204. Weblink.
Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. Lipoxin A4 attenuates adipose inflammation. FASEB Journal. 2012 Oct;26(10):4287-94, PMID: 22700871. Weblink.
Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB Journal. 2011 Sep;25(9):2967-79. PMID: 21628447. Weblink.
Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T. Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. Infection and Immunity 2011 Apr;79(4):1489-97, PMID: 21263017. Weblink.
Peer-Reviewed Review Articles
Kraft D. J., Blomgran R, Lundhaard I, Quiding-Järbrink M, Bromberg S.J. Börgeson E.* Specialized Pro-Resolving Mediators in the Lymphatic System. International Journal of Molecular Sciences. Weblink
Börgeson E.* The role of lipoxins in cardiometabolic physiology and disease. Cardiovascular Endocrinology Journal, November 2015. *Corresponding author. Invited review article.Weblink.
Börgeson E, Sharma K. Obesity, immunomodulation and chronic kidney disease. Current Opinion in Pharmacol. 2013 Aug;13(4):618-24. PMID: 23751262.Invited review article. Weblink.
Börgeson E, Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Frontiers in Immunology, 2012 Oct 18;3:318, PMID: 23087692.Invited review article.Weblink.
Börgeson E, Godson C. Molecular circuits of resolution in renal disease. The Scientific World Journal. 2010 Jul 7;10:1370-85, PMID: 20623097.Invited review article.Weblink.
